Histologic scoring indices for evaluation of disease activity in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  Novak, Gregor ^a,b   Parker, Claire E ^c   Lacey, Catherine ^d   Pai, Rish K ^e   Feagan, Brian G ^c,f   Sandborn, William J ^g   D'Haens, Geert ^h   Macdonald, John K ^c,f   Levesque, Barrett G ^c   Jairath, Vipul ^f   Khanna, Reena ^c,f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d RADY CHILDREN'S HOSPITAL   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; EVALUATION STUDY; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW;

EID: 84986268646     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012351     Document Type: Article

References (15)

1. Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?. Alimentary Pharmacology and Therapeutics 2002;16(5):857-67.
2. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clinical Gastroenterology and Hepatology 2015; Vol. 13, issue 6:1042-50.
3. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV Jr, Harmsen WS, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006;55:1561-7.
4. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114(2):262-7.
5. D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflammatory Bowel Diseases 2009;15(10):1599-1604.
6. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials 1991;12(4 Suppl):142S-58S.
7. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. Journal of Crohn's and Colitis 2012;6 Suppl 2:S224-34.
8. Kirshner B, Guyatt G. A methodological framework for assessing health indices. Journal of Chronic Diseases 1985;38(1):27-36.
9. Korelitz BI, Sommers SC. Response to drug therapy in Crohn's disease: evaluation by rectal biopsy and mucosal cell counts. Journal of Clinical Gastroenterology 1984;6:123-7.
10. Mojtahed A, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Shackelton LM, et al. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflammatory Bowel Diseases 2014;20(11):2092-103.
11. Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, et al. Achievement of deep remission during scheduled maintenance therapy with TNF α-blocking agents in IBD. Journal of Crohn's and Colitis 2013;7(9):730-5.
12. Naini BV, Cortina G. A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology 2012;43(12):2187-96.
13. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. British Medical Journal 1956;1:1315-18.
14. Ward N, Webb JN. Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology 1977;30:126-31.
15. Zou GY. Quantifying responsiveness of quality of life measures without an external criterion. Quality of Life Research 2005;14(6):1545-52.